The FDA approved sotatercept (Winrevair) for treating pulmonary arterial hypertension (PAH) in adults, Merck announced on Tuesday. A novel activin signaling inhibitor, sotatercept is indicated to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback